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Review Of RefeRence PRicing effects On PHaRmaceuticals
Zhou W., Cui X., Qian Y.
Sanofi China, Beijing, China
Objectives: Reference pricing has been popular used in many countries as a reim-
bursement policy to contain raising pharmaceutical expenditures since Germany 
first introduced in1989. China is under discussion concerning implementation of 
reference pricing for innovative drug pricing. This study is designed to overview 
the effects of reference pricing on health care helps to provide reference evidence 
to estimate the potential role of reference pricing for policy strategy making, and 
deliver the suggestion on benefit/risk analysis when adopting reference pricing in 
China. MethOds: We systematic reviewed published review studies or literatures 
based on empirical outcome effects analysis of reference pricing and present the 
common assess conclusion or views on the effect of reference pricing across all 
experiences, selected research covered different countries and backgrounds have lit-
tle coverage to keep the references outcomes diversity and little overlap. Results: 
Results shows that reference pricing could decreases drug prices include in system 
and original and generic drug price reductions are different according to pharma-
ceutical markets power. Reference pricing increases drug use of priced below or at 
the reference price. Reference pricing could save drug expenditures limited in the 
short-run but no sufficient evidence showed on the long-term expenditures reduc-
tion. Besides, no adverse effect was clearly found on patient access pharmaceutical 
services by reference pricing. cOnclusiOns: Evidences indicates that reference 
pricing seems to be effective for governments to contain pharmaceutical expendi-
tures and more research is need on the long-term effects and impact on different 
health care systems of reference pricing.
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Objectives: To study how to adjust the roles of pharmacists under the currently 
health insurance system; and how to perfect the mechanism for drug reimbursement 
list adjustment under China. current social health insurance system MethOds: 
China Pharmaceutical Industry Research and Development Association formulated 
the Questionnaire on the Roles of Pharmacists and the Health Insurance System. Survey 
was conducted to pharmacists and experts in relevant fields from early April 2013. 
By the middle of May, 152 questionnaires were returned, in which 141 ones were 
considered effective for the statistics. Results: As to the pharmacist system, 95% 
respondents agree to popularize the pharmacist system comprehensively in the 
hospitals. Respondents believe that pharmacists shall be entitled to the rights of 
verifying prescriptions, examining medication cost information, dispensing high 
quality drugs with preference, and participating in RDL adjustment. The majority 
of respondents (81.6%) agree to link the medical institutions and medical insurance 
agencies on line, which can better take advantage of pharmacistsrole. As to the RDL 
adjustment cycle, most respondents (78.7%) believe that current 4-year cycle is not 
reasonable, and more people (46.8%) think 2 years may be better. The respondents 
think that major problems in current RDL adjustment mechanism lie in the lack of 
evaluationstandards and procedures transparency. More people (61.0%) agree that 
the pharmacoeconomics evaluation shall be an essential basis for RDL adjustment 
decisions process. The survey results also show that at present, the system design 
for pharmacoeconomics application is not mature, and relevant capacity building 
and legislative guarantee are urgently required. cOnclusiOns: It has been a com-
monly recognization to improve the pharmacist system and strengthen the rights 
of pharmacist in prescription examination and drug dispensing. Evidence-based 
researches on how to shorten adjustment cycle, establish a transparent and open 
decision-making process, and attach importance to the pharmacoeconomics are 
major issues needing improvements in the present RDL adjustment mechanism.
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HOw dO ORganizatiOnal aRRangements Of tHe PHaRmaceutical 
suPPly system affect availability tO essential medicines  
in RuRal cHina?
Zuo G.
Shandong University, Jinan, China
Objectives: The manifold reasons lead to lack of availability to essential medicines, 
but higher price induced by pharmaceutical patent and organizational arrange-
ments of pharmaceutical supply system is main barrier. Since 2009, Chinese govern-
ment has constructed essential medicines policy of centralized purchasing, uniform 
distribution and “zero-mark-up” (i. e. no-profit) sale to supply essential medicines, 
all but generic drugs. This study aims to develop a theoretical methodology to 
examine the impact of organizational arrangements on availability to essential 
medicines. MethOds: We present a theoretical framework based on organizational 
economics to identify organizational boundary and inter-organization relationship 
of pharmaceutical supply system in order to define the stakeholders’ function and 
to find competition and cooperation relationship between them. We collect evidence 
from nine township hospitals at three counties of Shandong Province with different 
economic and geographical environment from July to August 2011. Organizational 
arrangements are identified by document review, interviews and focus group discus-
sions with stakeholders. Availability to essential medicines is measured as allocated 
rate and timeliness arrival rate of national essential medicines by questionnaire and 
online transaction records. Results: The mean allocated rate of national essential 
medicines was 51.47% because organizational boundary between stakeholders was 
so vague that the stakeholders’ function was not clear and pharmaceutical manu-
facturers didn’t receive the demand information of township hospitals. Timeliness 
arrival rate of national essential medicines within three days was from 33.77% 
Objectives: This study estimates the effect of national essential drug system on 
drug price and patient selection of pilot grass-root medical institution. MethOds: 
This study employs DID (difference-in-difference) method to investigate the effect 
of Essential Drug Regime Reform (EDRR) on drug price and patient selection of 
public grass-root medical institutions. Our sample comes from a Chinese city’s 
Urban Employee Basic Medical Insurance Reimbursement Dataset for inpatient 
care from 2009-2010. The full sample has 53416 observations including 2896 unique 
pharmaceutical firm-level products from 210 grass-root medical institutions. The 
dependent variable is the average price of each product in each month from each 
medical institution. The key independent variables are dummy variables indicating 
the pilot institutions (TREAT), the releasing time of Essential Drug Regime (EDR) 
and interaction of them (TREAT*EDR). Results: The results show that after the 
implementation of EDR, drug price on the pilot institutions decreased significantly 
by 37 percent (relative to control institution). Especially, essential drugs fell by 
43.3 percent relative to control institution. This policy has no significant effect on 
non-essential drugs. After the implementation of the national essential drug sys-
tem inpatient expenditures of the pilot medical institutions increased by 20.67%, 
length of stays increased by about three days, relative to the non-pilot medical 
institutions. After all, there is no change in patient co-payment rate. We found that 
patients more severe (diagnosed with more than one diseases) chose to go to the 
pilot medical institution increased by 7%. cOnclusiOns: The national essential 
drug systerm has signifcant effect on durg price, especially the essential drug, 
and the patients more severe prefered to go to the grass-root medical institution 
rather than levle-2 and level-3 hospitals.
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Objectives: Japanese government has promoted the use of generic drugs as 
means to decrease the burden to patients as well as to improve the situation of 
public finance sustainability. However, the proportion of generic prescriptions out 
of the total prescriptions written is lower compared to other developed countries. 
We thus examine the determinants of prescription of new and brand name drugs 
to understand what discourages Japanese physicians from prescribing generic 
drugs. MethOds: Using data from an original survey of 300 physicians conducted 
in September 2012. These surveys are analyzed with regard to the potential influ-
ence of the following factors: physicians’ information seeking behavior regard-
ing drugs, principal-agent relationship, risk and time preferences and physician 
characteristics. The analysis uses an ordered logistic regression model. Results: 
Our major findings are summarized as follows. First, it can be said that the propor-
tion of new drug prescriptions to all prescriptions rises as physicians’ intensity 
in information seeking behavior increases, but it is not significantly affected by 
principle-agent relationship or risk or time preferences. Second, the proportion of 
brand name drug prescriptions is positively associated with increased consideration 
of drug safety but negatively associated with that of drugs costs, pointing toward 
the hypothesis that the principal-agent relationship is an important factor. Third, 
time preference significantly determines the prescription of brand name drugs 
whereas risk preference does not. In particular, the more preferred is current con-
sumption over future consumption, the greater proportion of brand name drugs is 
prescribed. Neither risk nor time preferences significantly affects the proportion 
of prescription of new drugs. Finally, the impact of each determinant on prescrip-
tion behavior differs between internal medicine physicians and physicians in other 
areas of specialization. cOnclusiOns: Our empirical results suggest a limitation 
of uniform policies across physicians such as provision of financial incentives as 
means to the promotion of generic drug use.
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Siahaan S., Handayani R.S.
National Institute of Health Research and Development (NIHRD), Jakarta Pusat, Indonesia
Objectives: In 2014 Indonesia started National Health Insurance (NHI). This 
study aimed to search the existing evidence base on access to medicine issues to 
recommend policy options and model of medicines prices to be used in the era 
of NHI. MethOds: NIHRD conducted study at 2012 by reviewing several surveys 
results of access to medicines from 2004-2012 and organising several discussion 
forums about access to medicines. The participants were key persons from govern-
ment, private sectors, NGOs and other related stakeholders. Results: Indonesia 
medicines prices surveys using WHO-HAI method in 2004, 2010 and 2012 showed 
access to medicines problems still had similar patterns i. e. several district health 
offices bought medicines with higher prices than national standard prices and sev-
eral public hospitals sold several medicines with higher prices than private sectors. 
Most medicines prices (> 90%) were still higher than international reference price. 
The Median Price Ratios (MPRs) of medicines for public sector in Indonesia were 
1.74 (2004) and 1.52 (2012), while in Malaysia was 1.09 (2004) and in Thailand was 
1.46 (2006), but in Philippine was 2.06 (2009). The availability of medicines in public 
sectors was consistent lower than in private sectors. Study (2007) showed the avail-
ability of several essential and generic medicines in several public health facilities 
were enough for < 3 months. Study (2011) showed availability of FDC medicines for 
tuberculosis and ACT for malaria in endemic areas were inadequate (50%&70%). 
Discussion forums summarized main points: Medicines prices can be controlled 
by full time pharmacist if they serve rational drug use to patients. NHI has ability 
to control medicines prices, etc. cOnclusiOns: Pharmacy should not “mark-up” 
medicines prices, but charge pharmacist services fee to patients. The government 
should set up MPRs of medicines in the list of NHI formulary no more than 1.50 
and assure its availability, and NHI should implement pharmacoeconomics for new 
medicines.
